Safety, pharmacokinetics, and dosimetry of 177Lu-AB-3PRGD2 in patients with advanced integrin αvβ3-positive tumors: a first-in-human study

Update your browser to view ScienceDirect.

Request details:

Request ID: 8def5d200bb1ce94-LAX
IP: 116.62.10.13
UTC time: 2024-11-07T18:25:04+00:00
Browser: Mozilla/5.0 (X11; U; Linux x86_64; en-US; rv:1.9.1.4) Gecko/20091030 Gentoo Firefox/3.5.4